Mar. 21 at 1:24 AM
$PTN Looking at 13Fs, smart money is already positioned here. We are effectively holding the only oral competitor in a multi-billion dollar rare disease market that was just validated by the FDA.
$RYTM didn't just validate the science; it officially priced the market for the first time. Palatin is the oral version of a
$2-3billion per year market opportunity, yet it currently trades at a valuation that is only 0.6% of RYTM. By filing the IND after the RYTM approval, Palatin is perfectly timed to ride the wave of MC4R validation. If PTN reaches just 5% of Rhythm’s valuation, which is highly reasonable for a Phase 1 asset with superior oral delivery, the stock price could be ~
$185.00.
